Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks of and Mozobil(TM) and Synvisc-ONE(TM) are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Conference Call Information

Genzyme will host a conference call today at 11:00 a.m. Eastern to discuss results for the first quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and th
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 Dr. ... announced today that Roger L. Williams, MD, has ... NDA Partners Premier Experts are top tier consultants ... bring extraordinary value to the company’s clients. Premier ... to help clients successfully develop their medical products, ...
(Date:5/27/2015)... Mass. , May 27, 2015 ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today announced that it has commenced a public ... to purchase shares of its common stock and ... common stock. The shares of common stock, warrants ...
(Date:5/27/2015)... Expanding in a big way into the Japanese ... recently inked a deal with Arthur Mokuda, president ... the largest endodontic distributor in Japan. The move represents ... Biomed, which manufactures Grey MTA Plus® and the newly ... have won renown from dentists around the world. , ...
(Date:5/27/2015)... May 27, 2015 Empowering biomedical ... combat disease, Cubresa Inc. today announced its MR ... Compatible in-bore PET Scanner uses silicon photomultiplier detector ... preclinical MRI machines from manufacturers like Bruker and ... in Winnipeg, Canada. “This enables simultaneous PET and ...
Breaking Biology Technology:Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Cubresa Launches Simultaneous PET/MRI Technology 2
... de Bono, Peter Gabriel, HRH Prince Hassan, Malcolm McLaren, Carolyn ... Porco and Philippe Starck on judging ... Creative,Director of Saatchi & Saatchi, today announces the contenders to ... Held biennially, this global competition was established by Saatchi ...
... First Clinical Milestone Validates Approach, SAN FRANCISCO, ... completion of its first clinical trial, a,proof-of-concept study ... sodium channel blocker. Rufinamide was discovered and,developed by ... Europe as a,drug to treat a form of ...
... Progentix,Orthobiology B.V. announced today the closure of its ... BioGeneration Ventures., Progentix Orthobiology B.V. was established ... material products for clinical application,in bone regenerative surgery. ... ceramic biomaterial scaffolds that have the ability to,attract ...
Cached Biology Technology:Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 2Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 3Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 4Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 5Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2
(Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... policymakers to encourage the transition from coal-based electricity production to ... Such a mechanism would help limit carbon dioxide (CO ... in Copenhagen last December, the United States pledged to reduce ... percent by 2020. Dagobert Brito, the George A. ...
... DURHAM, N.C. -- Faced with threats such as habitat ... worldwide may become extinct before scientists can even discover them, ... American and British researchers in the journal Proceedings of ... overall, there could be between 5 million and 50 million ...
... NC In its early stages, prostate cancer requires ... male sex characteristics) for growth, and current first-line therapies ... development and spread. However, advanced prostate ... ineffective. Scientists aren,t sure how this shift occurs ...
Cached Biology News:Researchers calculate the cost of CO2 emissions, call for carbon tax 2Thousands of undiscovered plant species face extinction 2UNC team finds new target for treatment of advanced prostate cancer 2
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Performance, mycoplasma, virus, and endotoxin tested...
... and MagicMark XP Western Protein Standards ... convenient protein molecular weight estimation directly ... contains an IgG binding site, allowing ... reagents used to detect your target ...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: